Please assess the completion status of the following clinical trial:

Trial Title: Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of NPC-1 defined as one of the following~   1. Two NPC-1 mutations on exome gene sequencing~  2. One NPC-1 mutation and positive filipin staining (current or prior)~  3. Vertical supranuclear gaze palsy \[VSGP\] plus either ≥ one NPC-1 mutation or positive filipin staining and no NPC-2 mutations~2. NIH NPC Severity Score \<30 and with no more than 4 individual domains with a score ≥ 3.~3. Age range: 18 years upwards~4. At least one systemic manifestation of NPC disease defined as one or more of~   1. Clinically detectable hepatomegaly and/or either ALT or AST outside the normal range for the study laboratory~  2. Clinically detectable splenomegaly~  3. Impaired respiratory function due to NPC or a history of pneumonia in the last 12 months~5. Negative urine pregnancy test for females of child bearing potential~6. Written, informed consent~Exclusion Criteria:~1. The presence of NPC-2 mutations on exome gene sequencing~2. Previous receipt of cyclodextrin therapy within 3 months of baseline~3. Receipt of any of the following medications within 1 month of baseline: Coenzyme Q10, curcumin, cinnamon, fish oil supplements, high dose vitamin D (\>500 milli-International unit (mIU)/day), acetyl leucine, or gingko biloba~4. Concurrent treatment with any therapy indicated for the lowering of cholesterol such as statins, fibrates, ezetimibe~5. Karnofsky score \< 40~6. Inability to comply with the proposed protocol assessments or any uncertainty about their ability to give meaningful, informed consent (legal guardian may give consent with patient assent)~7. Concurrent medical conditions representing a contraindication to any of the study medications~8. Grade 3 renal impairment or worse as indicated by eGFR\< 60mL/min/1.73m2~9. Clinical evidence of acute liver disease including symptoms of jaundice or right upper quadrant pain or INR \>1.8~10. Involvement in another interventional clinical trial within the previous 6 months from baseline~11. Weight \<40 kg or \>100 kg~12. Male patients and female patients of childbearing potential who are not willing to use appropriate birth control (i.e. double barrier birth control) from enrolment until the follow-up visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxypropyl-beta-cyclodextrin IV 1500 mg/kg (Type: ACTIVE_COMPARATOR): Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks
- Hydroxypropyl-beta-cyclodextrin IV 2500 mg/kg (Type: ACTIVE_COMPARATOR): Hydroxypropyl-beta-cyclodextrin administered by slow IV infusion for 8 - 9h every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).